TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05100654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Study: NCT05848830

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mult-ingredient supplement
Description: A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent exercise training
Description: All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Concurrent exercise training
Description: All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
Study: NCT05819138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Semaglutide injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semaglutide placebo injection
Study: NCT06092138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Device
Description: Whether to use wearable devices.
Study: NCT05942937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Intervention (The HepPEd Program)
Description: All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format.
Study: NCT05448560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level Intervention of shared model of survivorship care
Description: 1) Patient survivorship education via telehealth with the cancer center- The research registered nurse (RN) will discuss the contents of the survivorship care plan and coordination between the cancer center and PCP clinic. 2) Ongoing patient-tailored education program by MyChart within the EHR patient portal- Patients will be asked to select survivorship topics of interest from a panel (e.g. school issues, fertility, fatigue, physical activity, single kidney health, emotions/coping) that will then be sent over 1 year. 3) Structured interactive phone communication between the research RN at the cancer center and community PCP clinic- The discussion will explain the patient's cancer history, tumor recurrence monitoring schedule, individualized risk of late effects and surveillance schedule, psychosocial challenges, health behaviors, and coordination between the cancer center and PCP clinic. 4) In-person visit with the PCP clinic for survivorship care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: Participants will be contacted by study staff at their cancer center to schedule an in-person visit at the survivorship clinic that will include a comprehensive history focused on cancer-related medical and psychosocial issues, physical examination, ordering of recommended surveillance for late effects, and delivery of hard copy of their survivorship care plan.
Study: NCT06393374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg intravenous (IV) infusion q6w

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg intravenous (IV) infusion q6w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Sacituzumab tirumotecan 4 mg/kg IV infusion q2w
Study: NCT05838833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-001
Description: Patient will be assigned to one of three arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-001
Description: Patient will be assigned to one of three arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INV-001
Description: Patient will be assigned to one of three arms.
Study: NCT05470894

Intervention type: BIOLOGICAL
Intervention: Approved COVID-19 vaccine
Description: Vaccination for COVI9-19
Study: NCT05113355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
Study: NCT06320119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDO Group
Description: Patients in the intervention gruop with set a personalized outcome within a usual asthma review consultation
Study: NCT06127888

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey
Study: NCT05745324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
Study: NCT06127888

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey
Study: NCT06177782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth modified scan bodies
Description: Tooth modified scan bodies are used during scanning for full arch implant cases.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional scan bodies
Description: Conventional scan bodies will be used for scanning the full arch implant cases.
Study: NCT06127888

Intervention type: OTHER
Intervention: Surveys
Description: Estructured survey
Study: NCT04770987

Intervention type: OTHER
Intervention: lateral neck flexor endurance test
Description: Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.

Intervention type: OTHER
Intervention: lateral neck flexor endurance test
Description: Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
Study: NCT05329818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation
Description: Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation
Description: Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation
Description: Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high definition transcranial direct current stimulation
Description: Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down.
Study: NCT04709302

Intervention type: BIOLOGICAL
Intervention: COVID-19
Description: Patients diagnosed with a COVID-19 infection

Intervention type: BIOLOGICAL
Intervention: COVID-19
Description: Patients diagnosed with a COVID-19 infection

Intervention type: BIOLOGICAL
Intervention: COVID-19
Description: Patients diagnosed with a COVID-19 infection

Intervention type: BIOLOGICAL
Intervention: HIV
Description: Patients diagnosed HIV-positive
Study: NCT06304636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-15
Description: Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-15
Description: Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-15
Description: Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
Study: NCT04924244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: We will play music of the subject's choice of genre during the procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Music
Description: No music will be played during the subject's interventional procedure
Study: NCT06004245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7589831
Description: RO7589831 will be administered orally and once daily (QD) in 3-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7589831
Description: RO7589831 will be administered orally and once daily (QD) in 3-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7589831
Description: RO7589831 will be administered orally and once daily (QD) in 3-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
Study: NCT05752136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
Study: NCT04526938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft
Description: Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
Study: NCT04858321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive heating
Description: 8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
Study: NCT06643728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: Administered SC
Study: NCT05707767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection surgery
Description: Patients undergo resection surgery in our hospital.
Study: NCT06376357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Massage with roller
Description: The intervention group is expected to apply roller massage to the soles of both feet in a sitting position on a chair (8 hours apart at 08.00, 16.00, 24.00 hours) every day for 6 weeks, 3x5 minutes a day. Video recording will be used as a reminder in the application.
Study: NCT04709302

Intervention type: BIOLOGICAL
Intervention: HIV
Description: Patients diagnosed HIV-positive
Study: NCT06393374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
Study: NCT04709302

Intervention type: DRUG
Intervention: ART
Description: Patients on ART
Study: NCT05382663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alio Device
Description: Non-invasive device worn over vasculature.
Study: NCT06411119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meta Oculus Quest 2™ Virtual Reality Exergaming
Description: Participants utilised the Meta Oculus Quest 2™ Virtual Reality headset to play the Beat Saber game, which involves striking blocks in time to music using hand controllers. Gameplay was configured at a moderate difficulty level in 'no-fail' mode to encourage continuous activity across pre-selected songs, requiring participants to perform movements such as lateral steps, squats, and arm motions. Each session lasted for 20 minutes, including 30-second rest intervals between songs, to maximise physical activity and monitor heart rate, perceived exertion, and technology acceptance.
Study: NCT05276050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active F8-coil delivered rTMS
Description: Multiple trains of rTMS in a day, for multiple days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active H-coil delivered rTMS
Description: Multiple trains of rTMS in a day, for multiple days.
Study: NCT05207384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone (O2-O3) injection
Description: US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Corticosteroid injection
Description: US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
Study: NCT04881760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05950191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)
Description: Next-generation bed net combining insecticides with different modes of action

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: long lasting insecticidal nets with PBO-pyrethroid (PermaNet)
Description: Next-generation bed net combining an insecticide with a synergist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Behavior Change Communication
Description: The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Behavior Change Communication
Description: The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
Study: NCT05803785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBC1501
Description: BBC1501 solution for Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBC1501
Description: BBC1501 solution for Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBC1501
Description: BBC1501 solution for Intravitreal injection
Study: NCT05047770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ/su
Description: 2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HZ/su
Description: 2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Flu D-QIV
Description: 1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Flu D-QIV
Description: 1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: 1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: 1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: 1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: 1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
Study: NCT01113021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon stimulation by low level laser therapy